Company Overview

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. The Company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable.

The Company's lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulation technology.

Stock Data

MTNB Symbol
NYSE American Market
Market Cap

Upcoming Events

28th European Congress of Clinical Microbiology and Infectious Disease

Madrid, Spain

Presentation Title: Efficacy of oral amphotericin B-cochleates for the prevention of invasive candidiasis caused by Candida albicans in mice
Presenting Author: David S. Perlin, Ph.D., Member of Matinas' Scientific Advisory Board, Executive Director of the Public Health Research Institute (PHRI) and the Rutgers Regional Biocontainment Laboratory (RBL) of New Jersey Medical School (NJMS), Rutgers Biomedical and Health Sciences, and Professor of Microbiology, Biochemistry and Molecular Genetics at NJMS
Date and Time: April 24, 2018 at 12:30 PM CET
Poster Presentation #: P2363
Session: Recent findings in invasive candidiasis

The ECCMID 2018 abstract is available online at the conference website.